We are live on ! Find out more
RNAZ icon

TransCode Therapeutics
RNAZ

9 hedge funds and large institutions have $237K invested in TransCode Therapeutics in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

3.32% more ownership

Funds ownership: 0.33% → 3.65% (+3.3%)

44% less funds holding

Funds holding: 16 → 9 (-7)

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

78% less capital invested

Capital invested by funds: $1.06M → $237K (-$823K)

78% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 9

Holders
9
Holders Change
-7
Holders Change %
-43.75%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
5
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$260K
2
TRCT
Tower Research Capital (TRC)
New York
+$3.21K
3
Bank of America
Bank of America
North Carolina
+$74
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$19

Top Sellers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
-$724K
2
SM
Sabby Management
Florida
-$113K
3
UBS Group
UBS Group
Switzerland
-$74K
4
WAM
Warberg Asset Management
Illinois
-$24.8K
5
CCM
Corsair Capital Management
New York
-$19.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
1
Goldman Sachs
New York
$219K +$260K +28,042 New
UBS Group
2
UBS Group
Switzerland
$11.2K -$74K -7,994 -85%
SC
3
SouthState Corp
Florida
$3.76K -$1.49K -161 -25%
TRCT
4
Tower Research Capital (TRC)
New York
$3.14K +$3.21K +347 +631%
SS
5
SBI Securities
Japan
$78 -$28 -3 -23%
Bank of America
6
Bank of America
North Carolina
$63 +$74 +8 New
Osaic Holdings
7
Osaic Holdings
Arizona
$23 -$9 -1 -25%
Fidelity Investments
8
Fidelity Investments
Massachusetts
$23 +$19 +2 +200%
AFM
9
Anson Funds Management
Texas
– -$724K -52,218 Closed
SM
10
Sabby Management
Florida
– -$113K -8,180 Closed
WAM
11
Warberg Asset Management
Illinois
– -$24.8K -1,786 Closed
CCM
12
Corsair Capital Management
New York
– -$19.8K -1,429 Closed
Acadian Asset Management
13
Acadian Asset Management
Massachusetts
– -$11K -797 Closed
Commonwealth Equity Services
14
Commonwealth Equity Services
Massachusetts
– -$11K -774 Closed
GSC
15
Ground Swell Capital
South Carolina
– -$7.11K -513 Closed
MG
16
Marex Group
– -$6.28K -453 Closed
Morgan Stanley
17
Morgan Stanley
New York
– -$2.48K -179 Closed
Royal Bank of Canada
18
Royal Bank of Canada
Ontario, Canada
– -$9 -1 -11%

RNAZ Hedge Fund Activity: Q2 2025 in Review

9 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in TransCode Therapeutics (RNAZ) for Q2 2025, worth a combined $237K — down 78% from $1.06M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of RNAZ and 2 opened new positions — a net loss of 7 holders — while 5 trimmed existing stakes and 2 added.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $260K. The largest seller was Anson Funds Management, exiting entirely with an estimated $724K sold.

  • 9 institutional investors held TransCode Therapeutics (RNAZ) as of Q2 2025, down from 16 in Q1 2025.
  • Funds reported $237K of TransCode Therapeutics stock for Q2 2025, down 78% quarter-over-quarter.
  • 2 funds opened new TransCode Therapeutics positions in Q2 2025 and 9 closed out, a net change of -7 holders.
  • The largest TransCode Therapeutics buyer in Q2 2025 was Goldman Sachs, an estimated $260K added.
  • The largest TransCode Therapeutics seller in Q2 2025 was Anson Funds Management, an estimated $724K sold.

Based on aggregated 13F filings for Q2 2025.